Abstract
Objective:
Our aim was to examine the clinicopathologic
characteristics and survival of ovarian, tubal, and peritoneal (further
denoted "adnexal") cancer in BRCA1 compared with BRCA2 carriers.
Methods: A consecutive series of adnexal cancers in
BRCA1/2 mutation carriers diagnosed in 1980 to 2010 at the University
Medical Center Groningen was analyzed.
Results:
We evaluated 55 BRCA1- and 16 BRCA2-related
adnexal cancers, consisting of 51 ovarian, 13 tubal, and 7 peritoneal
cancers. Peritoneal cancer was restricted to BRCA1 carriers. Ovarian and
tubal cancer was equally present in both carrier groups. Median age at
diagnosis was younger in BRCA1 compared with BRCA2 carriers (50 vs 54
years; P = 0.03). No other clinicopathologic differences were found.
Regarding survival, a nonsignificant trend was noted for BRCA2 carriers
to have fewer relapses, a longer time to first relapse, and a longer
disease-free and overall survival.
Conclusions: Except for age at diagnosis and prevalence
of peritoneal cancer, no significant clinicopathologic differences were
found between BRCA1- versus BRCA2-associated adnexal cancer. On
survival, it might be suggested that BRCA2 carriers have a more
favorable outcome than BRCA1 carriers, marked by fewer relapses, a
longer time to first relapse, and a longer disease-free and overall
survival.